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ischemia by 4!% (!), the number of patients with 160 min of transient 
myocardial ischemia decreased by 10% and silent episodes by 5%. 
These data ail suggest a reduction in transient rnyocardial ischemia 
when heparin is added to aspirin. However, the differences did not 
reach statistical significance, probably because of the small sample stze. 
The authors speculate “that 260 patients would be needed to give 
sufficient power (85%) to show a 70% reduction in transient myocar- 
dial ischemia.” According to our calculations, to achieve a similar 
power to show a more realistic 25% reduction, a sample size of 910 
patients would have been needed. The authors’ own data actually do 
suggest a reduction of this magnitude. In our opinion, to expect a 70% 
reduction in ischemia incidence from the addition of heparin to 
aspirin, a treatment modality in itself of proved efficacy, was quite 
unrealistic. 
Too small a sample size in randomized controlled trials having 
negative results seems to be a common error according to data 
published recently in JAMA (3). Of 102 such studies, only 16% and 
36% had sufficient statistical power to detect a 25% or SO% relative 
difference, respectively. 
We believe that the authors’ data do not support their conclusion 
that heparin plus aspirin is no more effective than aspirin alone in 
unstable angina pectoris. In fact, their data suggest but do not prove 
that heparin plus aspirin is more effective. To draw defnitive conclu- 
sions, a substantially bigger study involving -1,000 patients would be 
required. 
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Bode ct al. raise a point that should be asked when any compartson of 
different treatment strategies indicates the treatment modalities in 
question to be the same with respect to predefined end points. They 
suggest that an inadequate sample size may be responsible for our 
finding that combination therapy with heparin and aspirin was no 
different than aspirin alone in reducing the incidence of transient 
myocardial ischaemia in patients with unstable angina. We welcome 
the opportunity to defend our sample size calculation. 
The sample size was based on the expected incidence of transient 
myocardial ischemia and the effects of heparin and aspirin on transient 
myocardial ischemia. We indicated in the report that the calculations 
were made on the basis of data from the study by Semeri et al. (1) in 
which the etfects of heparin, aspirin and alteplase on myocardial 
iachcmia were compared in patients with unstable angina. Using 
continuous ST segmen: Iloiter monitoring they compared the effects 
of these treatments on the frequency of angina, number of silent 
ischemic episodes, total number of ischemic episodes and total dura- 
tion of ischemia. Their results indicated that treatment with heparin 
reduced angina1 episodes by 94%, silent ischemjc episodes by 71% 
total ischemic episodes by 78% and tota: duration of ischemia by 81% 
In contrast, aspirin had no significant effect. The typical odds reduction 
for recurrence of angina with heparin versus other treatments was 66% 
(SD 6.4%) for days 0 to 3 (p < 0.0013). On the basis of these results 
we believe that our original power calculation was reasonable. We 
estimated that 260 patients would be required to show a 70% reduction 
in transient myocardial ischemia with heparin and aspirin compared 
with aspirin alone, assuming a 20% incidence of transient ischemia in 
patients treated with aspirin, giving a power of 85%. Because some 
patients will be included who, in retrospect, will be diagnosed as having 
myocardial infarction, we increased the sample size by a further 10%. 
We believe that it is reasonable to expect a 70% reduction in ischemia 
with the addition of heparin because that is supported by the data from 
Serneri et al. (1). 
As Bodo et al. indicate, the sample size of any trial should be 
carefully inspected, but they should not be drawn into making state- 
ments about treatment guidelines by interpreting data “trends” when 
statistical significance is not reached. For example, they make several 
comments about the data in Table 2 from which they suggest that 
combination therapy is superior to aspirin. To state that the number of 
patients with transient myocardial ischemia was 25% less in the 
combination group is misleading when the absolute numbers of 
patients were 31 in the aspirin group versus 27 in the heparin and 
aspirin group-a difference of 4 patients. Similariy, tile other variables 
mentioned by Bodo et al. are particularly influenced by one patient in 
the aspirin group who r‘lntributed 1,360 min of transient ischemia, 
which constituted >25Y~ of the total ischemia in that group. We high- 
lighted the point in the text of our article. Consequently, we believe that 
Bodo et al. have no basis for suggesting that our data indicate that heparin 
and aspirin therapy is superior to aspirin alone. 
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Early Repair of Tetralogy of Fallot and 
Ventricular Arrhythmia 
It has been suggcstsd that in patients with tetralogy of Faliot, 
occurrence of late ventricular arrhythmias and possibly sudden death 
would decrease if surgical correction is performed early in life. The 
work of Joffe et al. (I) has attempted to address this important issue. 
This study describes the iong-term follow-up results in 29 patients after 
repair of tctraiogy of Fallot. 
“Early” versus “late” repair of tetralogy of Fallot is not clearly 
defined in published reports. Nevertheless, “early” commonly implies 
complete repair at the time of, or even before, development of the 
need for palliative surgery. which usually occurs during the first year of 
